GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Cara Therapeutics Inc (NAS:CARA) » Definitions » Forward PE Ratio

Cara Therapeutics (Cara Therapeutics) Forward PE Ratio : 0.00 (As of Apr. 26, 2024)


View and export this data going back to 2014. Start your Free Trial

What is Cara Therapeutics Forward PE Ratio?

Cara Therapeutics's Forward PE Ratio for today is 0.00.

Cara Therapeutics's PE Ratio without NRI for today is 0.00.

Cara Therapeutics's PE Ratio for today is 0.00.


Cara Therapeutics Forward PE Ratio Historical Data

The historical data trend for Cara Therapeutics's Forward PE Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Cara Therapeutics Forward PE Ratio Chart

Cara Therapeutics Annual Data
Trend
Forward PE Ratio

Cara Therapeutics Quarterly Data
Forward PE Ratio

Competitive Comparison of Cara Therapeutics's Forward PE Ratio

For the Biotechnology subindustry, Cara Therapeutics's Forward PE Ratio, along with its competitors' market caps and Forward PE Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Cara Therapeutics's Forward PE Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Cara Therapeutics's Forward PE Ratio distribution charts can be found below:

* The bar in red indicates where Cara Therapeutics's Forward PE Ratio falls into.



Cara Therapeutics Forward PE Ratio Calculation

It's a measure of the price-to-earnings ratio (PE Ratio) using forecasted earnings for the calculation. While the earnings used are just an estimate and are not as reliable as current earnings data, there is still benefit in estimated P/E analysis. The forecasted earnings used in the formula can either be for the next 12 months or for the next full-year fiscal period.


Cara Therapeutics  (NAS:CARA) Forward PE Ratio Explanation

The Forward PE Ratio of a company is often used to compare current earnings to estimated future earnings, as well as gaining a clearer picture of what earnings will look like without charges and other accounting adjustments. If earnings are expected to grow in the future, the Forward PE Ratio will be lower than the current PE Ratio. This measure is also used to compare one company to another with a forward-looking focus.

Trailing PE Ratio relies on what is already done. It uses the current share price and divides by the total EPS (Basic) over the past 12 months. PE Ratio can be affected by Non Operating Income such as the sale of part of businesses. This may increase for the current year or quarter dramatically. But it cannot be repeated over and over. Therefore PE Ratio without NRI is a more accurate indication of valuation than PE Ratio .


Cara Therapeutics Forward PE Ratio Related Terms

Thank you for viewing the detailed overview of Cara Therapeutics's Forward PE Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


Cara Therapeutics (Cara Therapeutics) Business Description

Traded in Other Exchanges
Address
107 Elm Street, 9th Floor, 4 Stamford Plaza, Stamford, CT, USA, 06902
Cara Therapeutics Inc is an emerging biotechnology company involved in the development of novel therapeutics to treat human diseases associated with inflammation, pain, and pruritus. Cara's most advanced compound, CR845, aims to treat acute pain and pruritus. This patented compound has analgesic, anti-inflammatory, and antipruritic properties that can be used for multiple therapeutic applications. Additionally, Cara's objective is to use its proprietary drug-screening technology to develop a future pipeline of first-in-class molecules with analgesic and anti-inflammatory features.
Executives
Christopher Posner director C/O CARA THERAPEUTICS, INC., 4 STAMFORD PLAZA, 107 ELM STREET, 9TH FL, STAMFORD CT 06902
Helen M Boudreau director 200 TECHNOLOGY SQUARE, 4TH FLOOR, CAMBRIDGE MA 02139
Joana Goncalves officer: Chief Medical Officer C/O CARA THERAPEUTICS, INC., 4 STAMFORD PLAZA, 107 ELM STREET, 9TH FL, STAMFORD CT 06902
Scott Terrillion officer: Sec'y; Chief Compliance & G.C. C/O CARA THERAPEUTICS, INC., 4 STAMFORD PLAZA, 107 ELM STREET, 9TH FL, STAMFORD CT 06902
Menzaghi Frederique Ph.d. officer: VP-Research & Development C/O CARA THERAPEUTICS, INC., 1 PARROTT DRIVE, SHELTON CT 06484
Moltke Lisa Von director C/O SERESTHERAPEUTICS, INC., 200 SIDNEY STREET, CAMBRIDGE MA 02139
Martin Vogelbaum director 675 ALMANOR AVE, SUNNYVALE CA 94085
Ryan D Maynard officer: Chief Financial Officer RIGEL PHARMACEUTICALS, INC., 1180 VETERANS BLVD., SOUTH SAN FRANCISCO CA 94080
Csl Ltd 10 percent owner
Jeffrey L. Ives director C/O CARA THERAPEUTICS, INC., 1 PARROTT DRIVE, SHELTON CT 06484
Bains Harrison M Jr director
Thomas Charles Reilly officer: Chief Financial Officer C/O CARA THERAPEUTICS, INC., 4 STAMFORD PLAZA, 107 ELM STREET, STAMFORD CT 06902
Vifor Fresenius Medical Care Renal Pharma Ltd. 10 percent owner RECHENSTRASSE 37, CH-9014, ST. GALLEN V8 9014
Vifor (international) Ltd 10 percent owner RECHENSTRASSE 37, ST. GALLEN V8 9000
Vifor Pharma Ltd. 10 percent owner UNTERMATTWEG 8, BERNE V8 CH-3027